Clinical trials: Severe Community-Acquired Pneumonia
- Condition Severe Community-Acquired Pneumonia
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Pneumonia
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
- Trial name
- NCT00084071
- Testing
- Tifacogin
- Where
- 150 sites in United States, Argentina and 16 more
- Volunteers
- 2,136 people
- Sponsor
- Novartis Pharmaceuticals